• +91 9169164321 (Asia)
  • +1(646)-781-7170 (Int'l)
  • help@24lifesciences.com
Cart (0)

COVID-19 Impact on Neuroprotection Market, Global Research Reports 2020-2021

report cover
  • 20 May 2020
  • Pharmaceuticals
  • 95 Pages
  • Report Code: 24LS-2852
  • Formate :   
Download FREE Report Sample Download PDF File

COVID 19 Impact Neuroprotecti Market Reports -MARKET ADVISORY SERVICES

This report covers market size and forecasts of Neuroprotection, including the following market information:
Global Neuroprotection Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Neuroprotection Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Neuroprotection Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Neuroprotection Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)

Key market players
Major competitors identified in this market include F. Hoffmann-La Roche, Eli Lilly and Company, Daiichi Sankyo Company, Allergan, Novartis, AstraZeneca, Dr. Reddy's Laboratories, Astrocyte Pharmaceuticals, Teva Pharmaceutical Industries, Biogen, etc.

Based on the Region:
Asia-Pacific (China, Japan, South Korea, India and ASEAN)
North America (US and Canada)
Europe (Germany, France, UK and Italy)
Rest of World (Latin America, Middle East & Africa)

Based on the Type:
Free Anti-Inflammatory Agents
Radical Trapping Agents (Antioxidants)
Apoptosis Inhibitors
Glutamate Antagonists (Anti-Excitotoxic Agents)
Neurotrophic Factors (NTFs)
Stimulants
Metal Ion Chelators
Other Products

Based on the Application:
Prevention
Treatment
1.1 Research Scope
1.2 Market Segmentation
1.3 Research Objectives
1.4 Research Methodology
1.4.1 Research Process
1.4.2 Data Triangulation
1.4.3 Research Approach
1.4.4 Base Year
1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.5.2 Covid-19 Impact: Commodity Prices Indices
1.5.3 Covid-19 Impact: Global Major Government Policy
1.6 The Covid-19 Impact on Neuroprotection Industry
1.7 COVID-19 Impact: Neuroprotection Market Trends

2 Global Neuroprotection Quarterly Market Size Analysis
2.1 Neuroprotection Business Impact Assessment - COVID-19
2.1.1 Global Neuroprotection Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
2.2 Global Neuroprotection Quarterly Market Size 2020-2021
2.3 COVID-19-Driven Market Dynamics and Factor Analysis
2.3.1 Drivers
2.3.2 Restraints
2.3.3 Opportunities
2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020
3.1 By Players, Global Neuroprotection Quarterly Market Size, 2019 VS 2020
3.2 By Players, Neuroprotection Headquarters and Area Served
3.3 Date of Key Players Enter into Neuroprotection Market
3.4 Key Players Neuroprotection Product Offered
3.5 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on Neuroprotection Segments, By Type
4.1 Introduction
1.4.1 Free Anti-Inflammatory Agents
1.4.2 Radical Trapping Agents (Antioxidants)
1.4.3 Apoptosis Inhibitors
1.4.4 Glutamate Antagonists (Anti-Excitotoxic Agents)
1.4.5 Neurotrophic Factors (NTFs)
1.4.6 Stimulants
1.4.7 Metal Ion Chelators
1.4.8 Other Products
4.2 By Type, Global Neuroprotection Market Size, 2019-2021

5 Impact of Covid-19 on Neuroprotection Segments, By Application
5.1 Overview
5.5.1 Prevention
5.5.2 Treatment
5.2 By Application, Global Neuroprotection Market Size, 2019-2021
5.2.1 By Application, Global Neuroprotection Market Size by Application, 2019-2021

6 Geographic Analysis
6.1 Introduction
6.2 North America
6.2.1 Macroeconomic Indicators of US
6.2.2 US
6.2.3 Canada
6.3 Europe
6.3.1 Macroeconomic Indicators of Europe
6.3.2 Germany
6.3.3 France
6.3.4 UK
6.3.5 Italy
6.4 Asia-Pacific
6.4.1 Macroeconomic Indicators of Asia-Pacific
6.4.2 China
6.4.3 Japan
6.4.4 South Korea
6.4.5 India
6.4.6 ASEAN
6.5 Rest of World
6.5.1 Latin America
6.5.2 Middle East and Africa

7 Company Profiles
7.1 F. Hoffmann-La Roche
7.1.1 F. Hoffmann-La Roche Business Overview
7.1.2 F. Hoffmann-La Roche Neuroprotection Quarterly Revenue, 2020
7.1.3 F. Hoffmann-La Roche Neuroprotection Product Introduction
7.1.4 F. Hoffmann-La Roche Response to COVID-19 and Related Developments
7.2 Eli Lilly and Company
7.2.1 Eli Lilly and Company Business Overview
7.2.2 Eli Lilly and Company Neuroprotection Quarterly Revenue, 2020
7.2.3 Eli Lilly and Company Neuroprotection Product Introduction
7.2.4 Eli Lilly and Company Response to COVID-19 and Related Developments
7.3 Daiichi Sankyo Company
7.3.1 Daiichi Sankyo Company Business Overview
7.3.2 Daiichi Sankyo Company Neuroprotection Quarterly Revenue, 2020
7.3.3 Daiichi Sankyo Company Neuroprotection Product Introduction
7.3.4 Daiichi Sankyo Company Response to COVID-19 and Related Developments
7.4 Allergan
7.4.1 Allergan Business Overview
7.4.2 Allergan Neuroprotection Quarterly Revenue, 2020
7.4.3 Allergan Neuroprotection Product Introduction
7.4.4 Allergan Response to COVID-19 and Related Developments
7.5 Novartis
7.5.1 Novartis Business Overview
7.5.2 Novartis Neuroprotection Quarterly Revenue, 2020
7.5.3 Novartis Neuroprotection Product Introduction
7.5.4 Novartis Response to COVID-19 and Related Developments
7.6 AstraZeneca
7.6.1 AstraZeneca Business Overview
7.6.2 AstraZeneca Neuroprotection Quarterly Revenue, 2020
7.6.3 AstraZeneca Neuroprotection Product Introduction
7.6.4 AstraZeneca Response to COVID-19 and Related Developments
7.7 Dr. Reddy's Laboratories
7.7.1 Dr. Reddy's Laboratories Business Overview
7.7.2 Dr. Reddy's Laboratories Neuroprotection Quarterly Revenue, 2020
7.7.3 Dr. Reddy's Laboratories Neuroprotection Product Introduction
7.7.4 Dr. Reddy's Laboratories Response to COVID-19 and Related Developments
7.8 Astrocyte Pharmaceuticals
7.8.1 Astrocyte Pharmaceuticals Business Overview
7.8.2 Astrocyte Pharmaceuticals Neuroprotection Quarterly Revenue, 2020
7.8.3 Astrocyte Pharmaceuticals Neuroprotection Product Introduction
7.8.4 Astrocyte Pharmaceuticals Response to COVID-19 and Related Developments
7.9 Teva Pharmaceutical Industries
7.9.1 Teva Pharmaceutical Industries Business Overview
7.9.2 Teva Pharmaceutical Industries Neuroprotection Quarterly Revenue, 2020
7.9.3 Teva Pharmaceutical Industries Neuroprotection Product Introduction
7.9.4 Teva Pharmaceutical Industries Response to COVID-19 and Related Developments
7.10 Biogen
7.10.1 Biogen Business Overview
7.10.2 Biogen Neuroprotection Quarterly Revenue, 2020
7.10.3 Biogen Neuroprotection Product Introduction
7.10.4 Biogen Response to COVID-19 and Related Developments

8 Key Findings

9 Appendix
9.1 About US
9.2 Disclaimer
List of Tables

Table 1. Overview of the World Economic Outlook Projections

Table 2. Summary of World Real per Capita Output (Annual percent change; in international currency at purchasing power parity)

Table 3. European Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)

Table 4. Asian and Pacific Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)

Table 5. Western Hemisphere Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)

Table 6. Middle Eastern and Central Asian Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)

Table 7. Covid-19 Impact: Global Major Government Policy

Table 8. The Covid-19 Impact on Neuroprotection Assessment

Table 9. COVID-19 Impact: Neuroprotection Market Trends

Table 10. COVID-19 Impact Global Neuroprotection Market Size

Table 11. Global Neuroprotection Quarterly Market Size, 2020 (US$ Million)

Table 12. Global Neuroprotection Market Size, Pre-COVID-19 and Post- COVID-19 Quarterly Comparison, 2020-2021 (US$ Million)

Table 13. Global Neuroprotection Market Growth Drivers

Table 14. Global Neuroprotection Market Restraints

Table 15. Global Neuroprotection Market Opportunities

Table 16. Global Neuroprotection Market Challenges

Table 17. By Players, Neuroprotection Quarterly Revenue, 2019 VS 2020 (US$ Million)

Table 18. Key Players, Neuroprotection Revenue Market Share, 2019 VS 2020 (%)

Table 19. Key Neuroprotection Players Headquarters and Area Served

Table 20. Date of Key Players Enter into Neuroprotection Market

Table 21. Key Players Neuroprotection Product Type

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. By Players, Global Neuroprotection Market Size 2019-2021, (US$ Million)

Table 24. Global Neuroprotection Market Size by Application: 2019-2021 (US$ Million)

Table 25. Global Neuroprotection Market Size by Region, 2019-2021 (US$ Million)

Table 26. By Country, North America Neuroprotection Market Size, 2019-2021 (US$ Million)

Table 27. By Type, US Neuroprotection Market Size, 2019-2021 (US$ Million)

Table 28. By Application, US Neuroprotection Market Size, 2019-2021 (US$ Million)

Table 29. By Type, Canada Neuroprotection Market Size, 2019-2021 (US$ Million)

Table 30. By Application, Canada Neuroprotection Market Size, 2019-2021 (US$ Million)

Table 31. Macroeconomic Indicators of Europe (Germany, France, UK and Italy)

Table 32. By Country, Europe Neuroprotection Market Size, 2019-2021 (US$ Million)

Table 33. By Type, Germany Neuroprotection Market Size, 2019-2021 (US$ Million)

Table 34. By Application, Germany Neuroprotection Market Size, 2019-2021 (US$ Million)

Table 35. By Type, France Neuroprotection Market Size, 2019-2021 (US$ Million)

Table 36. By Application, France Neuroprotection Market Size, 2019-2021 (US$ Million)

Table 37. By Type, UK Neuroprotection Market Size, 2019-2021 (US$ Million)

Table 38. By Application, UK Neuroprotection Market Size, 2019-2021 (US$ Million)

Table 39. By Type, Italy Neuroprotection Market Size, 2019-2021 (US$ Million)

Table 40. By Application, Italy Neuroprotection Market Size, 2019-2021 (US$ Million)

Table 41. Macroeconomic Indicators of Asia-Pacific (China, Japan, South Korea, India and ASEAN)

Table 42. By Region, Asia-Pacific Neuroprotection Market Size, 2019-2021 (US$ Million)

Table 43. By Type, China Neuroprotection Market Size, 2019-2021 (US$ Million)

Table 44. By Application, China Neuroprotection Market Size, 2019-2021 (US$ Million)

Table 45. By Type, Japan Neuroprotection Market Size, 2019-2021 (US$ Million)

Table 46. By Application, Japan Neuroprotection Market Size, 2019-2021 (US$ Million)

Table 47. By Type, South Korea Neuroprotection Market Size, 2019-2021 (US$ Million)

Table 48. By Application, South Korea Neuroprotection Market Size, 2019-2021 (US$ Million)

Table 49. By Type, India Neuroprotection Market Size, 2019-2021 (US$ Million)

Table 50. By Application, India Neuroprotection Market Size, 2019-2021 (US$ Million)

Table 51. By Type, ASEAN Neuroprotection Market Size, 2019-2021 (US$ Million)

Table 52. By Application, ASEAN Neuroprotection Market Size, 2019-2021 (US$ Million)

Table 53. By Type, Latin America Neuroprotection Market Size, 2019-2021 (US$ Million)

Table 54. By Application, Latin America Neuroprotection Market Size, 2019-2021 (US$ Million)

Table 55. By Type, Middle East and Africa Neuroprotection Market Size, 2019-2021 (US$ Million)

Table 56. By Application, Middle East and Africa Neuroprotection Market Size, 2019-2021 (US$ Million)

Table 57. F. Hoffmann-La Roche Business Overview

Table 58. F. Hoffmann-La Roche Neuroprotection Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020

Table 59. F. Hoffmann-La Roche Neuroprotection Product

Table 60. F. Hoffmann-La Roche Response to COVID-19 and Related Developments

Table 61. Eli Lilly and Company Business Overview

Table 62. Eli Lilly and Company Neuroprotection Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020

Table 63. Eli Lilly and Company Neuroprotection Product

Table 64. Eli Lilly and Company Response to COVID-19 and Related Developments

Table 65. Daiichi Sankyo Company Business Overview

Table 66. Daiichi Sankyo Company Neuroprotection Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020

Table 67. Daiichi Sankyo Company Neuroprotection Product

Table 68. Daiichi Sankyo Company Response to COVID-19 and Related Developments

Table 69. Allergan Business Overview

Table 70. Allergan Neuroprotection Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020

Table 71. Allergan Neuroprotection Product

Table 72. Allergan Response to COVID-19 and Related Developments

Table 73. Novartis Business Overview

Table 74. Novartis Neuroprotection Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020

Table 75. Novartis Neuroprotection Product

Table 76. Novartis Response to COVID-19 and Related Developments

Table 77. AstraZeneca Business Overview

Table 78. AstraZeneca Neuroprotection Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020

Table 79. AstraZeneca Neuroprotection Product

Table 80. AstraZeneca Response to COVID-19 and Related Developments

Table 81. Dr. Reddy's Laboratories Business Overview

Table 82. Dr. Reddy's Laboratories Neuroprotection Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020

Table 83. Dr. Reddy's Laboratories Neuroprotection Product

Table 84. Dr. Reddy's Laboratories Response to COVID-19 and Related Developments

Table 85. Astrocyte Pharmaceuticals Business Overview

Table 86. Astrocyte Pharmaceuticals Neuroprotection Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020

Table 87. Astrocyte Pharmaceuticals Neuroprotection Product

Table 88. Astrocyte Pharmaceuticals Response to COVID-19 and Related Developments

Table 89. Teva Pharmaceutical Industries Business Overview

Table 90. Teva Pharmaceutical Industries Neuroprotection Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020

Table 91. Teva Pharmaceutical Industries Neuroprotection Product

Table 92. Teva Pharmaceutical Industries Response to COVID-19 and Related Developments

Table 93. Biogen Business Overview

Table 94. Biogen Neuroprotection Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020

Table 95. Biogen Neuroprotection Product

Table 96. Biogen Response to COVID-19 and Related Developments

List of Figures

Figure 1. Neuroprotection Product Picture

Figure 2. Neuroprotection Market Segmentation

Figure 3. Research Objectives

Figure 4. Research Process

Figure 5. Data Triangulation

Figure 6. Research Approach

Figure 7. Commodity Prices-Metals Price Indices

Figure 8. Commodity Prices- Precious Metal Price Indices

Figure 9. Commodity Prices- Agricultural Raw Material Price Indices

Figure 10. Commodity Prices- Food and Beverage Price Indices

Figure 11. Commodity Prices- Fertilizer Price Indices

Figure 12. Commodity Prices- Energy Price Indices

Figure 13. G20+: Economic Policy Responses to COVID-19

Figure 14. Global Neuroprotection Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 (US$ Million)

Figure 15. Global Neuroprotection Market Size, Pre-COVID-19 and Post- COVID-19, Year-over-Year Growth Rate, 2015-2026 (%)

Figure 16. Global Neuroprotection Market Size, Quarterly Growth, 2020-2021 (%)

Figure 17. Global Neuroprotection Market Size, Market Share by Type, 2019 VS 2020 (%)

Figure 18. Global Neuroprotection Market Size, Market Share by Application, 2019 VS 2020 (%)

Figure 19. Global Neuroprotection Market Size Market Share by Region, 2019 VS 2020 (%)

Figure 20. United States Composite PMI and GDP

Figure 21. Eurozone Composite PMI and GDP

Figure 22. Eurozone Core v. Periphery PMI Output Indices

Figure 23. Core v. Periphery PMI Employment Indices

Figure 24. UK Composite PMI and GDP

Figure 25. Caixin China Composite Output Index

Figure 26. Caixin China General Services Business Activity Index

Figure 27. Japan Composite Output Index

Figure 28. South Korea Manufacturing PMI

Figure 29. India Composite Output Index

Figure 30. ASEAN Manufacturing PMI

Figure 31. By Region, Asia-Pacific Neuroprotection Market Size Market Share, 2019-2021

F. Hoffmann-La Roche

Eli Lilly and Company

Daiichi Sankyo Company

Allergan

Novartis

AstraZeneca

Dr. Reddy's Laboratories

Astrocyte Pharmaceuticals

Teva Pharmaceutical Industries

Biogen

CHOOSE YOUR BUYING OPTION COVID-19 Revised Pricing Of the Month

SECURITY ASSUREDpayment image

Frequently Asked Questions ?

  • A license granted to one user.

    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License

    A license granted to multiple users.

  • Site License

    A license granted to a single business site/establishment.

  • Corporate License, Global License

    A license granted to all employees within organisation access to the product.

  • Upto Working 24 to 48 hrs

  • Upto 72 hrs max - Weekends and Public Holidays

  • Online Payments with PayPal and CCavenue

  • Wire Transfer/Bank Transfer

  • Email

  • Hard Copy

CHECK TODAYS BEST PRICE

BEST PRICE: $2438

SOME OF OUR CLIENTS

OUR KEY POINTS

  • Comprehensive Research

    Offers Penetrative insights & holistic understanding of the market

  • Data Accuracy & Reliability

    Strictly follows the Research Meth-odology for flawless results

  • Competitive Pricing

    Ensure the best and affordable pricing

  • Security & Confidentiality

    All your transactions are secured end-to-end, ensuring a satisfactory purchase